In case you missed it: Feb. 14 to Feb. 18
It was a busy week for the Contemporary OB/GYN® team.
This week's top articles included:
Cardiologist confirmed to head FDA
Robert Califf was approved in a 50-46 vote by the senate.
Price transparency in hospitals remains elusive, in spite of rule
Just 14.3% of hospitals complying with rule meant to encourage consumer price shopping.
Postmenopausal vulvovaginal discomfort
Postmenopausal vaginal symptom severity is not significantly linked to vaginal microbiota or mucosal inflammatory markers, according to a small study in the American Journal of Gynecology & Obstetrics.
Risk of rheumatoid arthritis with endometriosis
Patients with endometriosis are nearly four times as likely to develop rheumatoid arthritis (RA) than those without endometriosis, according to a study in the Journal of Women’s Health.
Oral ibrexafungerp for treating acute VVC
Patients with acute vulvovaginal candidiasis (VVC) greatly benefited from oral ibrexafungerp (Brexafemme, Scynexis), according to results of a global phase 3 randomized, double-blind, placebo-controlled superiority study published in the international journal of obstetrics and gynecology, BJOG.
Impact of dual burden differs by insurance type
Risk factors for the dual burden of severe maternal morbidity and preterm birth differ significantly by insurance type across sociodemographic and perinatal considerations in the state of California, according to a study in the Maternal and Children Health Journal.
